# Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction

> **NCT02788747** · PHASE2 · COMPLETED · sponsor: **Stealth BioTherapeutics Inc.** · enrollment: 71 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** 4 mg elamipretide
- **DRUG:** 40 mg elamipretide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02788747
- **Lead sponsor:** Stealth BioTherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2017-09
- **Final completion:** 2017-10
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2020-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02788747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02788747, "Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02788747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*